These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 23231395)

  • 1. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Curr Top Med Chem; 2012; 12(20):2177-88. PubMed ID: 23231395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
    Naoi M; Maruyama W; Inaba-Hasegawa K; Akao Y
    Int Rev Neurobiol; 2011; 100():85-106. PubMed ID: 21971004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
    Naoi M; Maruyama W; Akao Y; Yi H; Yamaoka Y
    J Neural Transm Suppl; 2006; (71):67-77. PubMed ID: 17447417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
    Naoi M; Maruyama W
    Curr Pharm Des; 2010; 16(25):2799-817. PubMed ID: 20698822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2012 Apr; 119(4):405-14. PubMed ID: 22065207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2018 Nov; 125(11):1635-1650. PubMed ID: 29279995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
    Yi H; Akao Y; Maruyama W; Chen K; Shih J; Naoi M
    J Neurochem; 2006 Jan; 96(2):541-9. PubMed ID: 16336631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
    Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Jan; 120(1):83-9. PubMed ID: 22892822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival.
    Naoi M; Maruyama W; Yi H; Inaba K; Akao Y; Shamoto-Nagai M
    J Neural Transm (Vienna); 2009 Nov; 116(11):1371-81. PubMed ID: 19763773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs related to monoamine oxidase activity.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
    Naoi M; Maruyama W; Shamoto-Nagai M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.